Why Is HCAT Stock Dropping Today? Health Catalyst Falls After Lowering Guidance

Health Catalyst (HCAT) shares fell 23.38% in intraday trading on Friday after the company cut its full-year and third-quarter revenue guidance, overshadowing a second-quarter earnings beat.

What Did Health Catalyst Report?

For the second quarter of 2026, Health Catalyst delivered revenue and adjusted earnings per share that came in above Wall Street consensus estimates. The quarterly beat, however, was not the story investors seized on. Management lowered full-year 2026 revenue guidance to a range of $246 million to $249 million. The company also set third-quarter revenue guidance at $55 million to $56 million, a significant miss relative to the $62.8 million consensus that analysts had been modeling -- a shortfall of roughly 11% to 12% at the midpoint.

The company attributed the reduced outlook to two structural changes. The first is the divestiture of its Vitalware business, which closed on July 31 and removed a revenue stream from the consolidated results. The second is the ongoing cost and complexity of migrating customers from the company's legacy DOS platform to its newer Ignite platform, a cloud-native data and analytics operating system.

Why Did Investors React Negatively?

The sell-off signals that the market is prioritizing the forward outlook over the backward-looking quarterly beat. The guidance cut is not a one-quarter stumble driven by transient headwinds. It is a material reset in revenue expectations tied to structural business changes that will take multiple quarters to play out.

The Vitalware sale removes a revenue-generating asset. The Ignite migration is a shift from an older on-premise deployment model toward a cloud-native offering. While the strategic logic of moving to a modern platform may be sound over the longer term, the near-term costs, implementation complexity, and customer transition risk are weighing on sentiment. For a company that investors have historically valued on revenue growth trajectory, a double-digit percentage cut to the full-year outlook leaves little room for the market to look past the headline numbers. The guidance reset also raises questions about whether Ignite's revenue contribution will ramp quickly enough to offset the headwinds from the divestiture and the legacy DOS business.

Those questions set the stage for what happens next.

What Should Investors Watch Next?

The 23.38% intraday decline was accompanied by volume running at roughly twice the 20-day average, suggesting broad-based conviction behind the selling. The move is unfolding during the regular trading session, which provides more reliable price discovery than pre-market or after-hours trading.

The risks are tied to execution. Migrating customers from DOS to Ignite involves implementation costs, potential service disruption, and uncertainty around adoption timelines. If the transition takes longer than expected or customer churn runs above management's assumptions, the revenue reset could extend beyond the current guidance period. The divestiture of Vitalware also removes diversification from the revenue base.

Investors will look to the earnings conference call for management's timeline on the Ignite migration and any color on when revenue growth might stabilize. Analyst model revisions in the days following the guidance cut will shape near-term sentiment and could determine whether the stock finds a floor or continues to reprice lower. The regular-session close will offer a clearer read on whether institutional investors are absorbing the sell-off or continuing to reduce positions.